Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Choice and Death: Analysis of Medical Assistance in Dying for Head and Neck Cancer in Ontario.

The Laryngoscope·2026

Same author

The Economic Burden of Management of Pituitary Adenomas: A Propensity-Score-Matched Cost Analysis.

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale·2025

Same author

Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2023

Same author

Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic review.

Pituitary·2022

Same author

Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.

Pituitary·2022

Same author

Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale·2022

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation

Published on: June 20, 2018

Canadian Real-World Study Long-Term Clinical Results Using Dupilumab for Chronic Rhinosinusitis With Polyps.

Shaun J Kilty¹, Andrea Lasso²

¹Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada.

Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale

|September 30, 2024

Summary

Dupilumab treatment for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) significantly improves quality of life for up to three years. Real-world data shows sustained symptom reduction in CRSwNP patients on dupilumab therapy.

Keywords:

SNOT-22 monoclonal antibody nasal polyps

More Related Videos

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Related Experiment Videos

Last Updated: Jun 26, 2026

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation

Published on: June 20, 2018

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Area of Science:

Immunology
Otolaryngology
Pharmacology

Background:

Dupilumab, an anti-IL4 receptor-α antibody, is the first biologic approved in Canada for CRSwNP.
Clinical trials show dupilumab reduces polyp size, symptom severity, and improves quality of life with an acceptable safety profile.
This study presents long-term, real-world data on sinonasal outcomes for CRSwNP patients treated with dupilumab for up to three years.

Purpose of the Study:

To evaluate the long-term, real-world effectiveness of dupilumab in treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
To assess sustained improvements in disease-specific sinonasal outcomes and quality of life for CRSwNP patients up to three years post-treatment initiation.

Main Methods:

Retrospective review of electronic medical records from a Canadian rhinology center.
Inclusion of CRSwNP patients who received dupilumab and completed at least one follow-up visit.
Utilized the Sino-Nasal Outcome Test (SNOT-22) to measure symptom improvement.

Main Results:

Ninety-nine patients initiated dupilumab therapy.
Mean SNOT-22 scores decreased significantly from 61.1 at baseline to 16.75 after 1 year, 15.02 after 2 years, and 10.22 after 3 years.
The study observed sustained improvements in sinonasal outcomes and quality of life over the three-year treatment period.

Conclusions:

Real-world data confirms dupilumab maintains significant improvements in disease-specific quality of life for CRSwNP patients up to three years.
Dupilumab demonstrates sustained efficacy in managing CRSwNP symptoms and improving patient outcomes in a clinical setting.
Long-term dupilumab treatment is associated with continued benefits for patients suffering from Chronic Rhinosinusitis with Nasal Polyps.